Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. [electronic resource]
Producer: 20151008Description: 211-6 p. digitalISSN:- 1432-0843
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Bendamustine Hydrochloride
- Electrocardiography -- drug effects
- Female
- Heart Rate -- drug effects
- Humans
- Lymphoma, Mantle-Cell -- drug therapy
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- Nitrogen Mustard Compounds -- administration & dosage
- Rituximab
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.